Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Withdrawn1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

withdrawn133%
terminated133%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

NCT05009979
withdrawnphase_1

PSMA Therapy and Immunotherapy in Kidney Cancer

NCT06361810
unknown

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

NCT04809584

Clinical Trials (3)

Showing 3 of 3 trials
NCT05009979Phase 2

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Terminated
NCT06361810Phase 1

PSMA Therapy and Immunotherapy in Kidney Cancer

Withdrawn
NCT04809584

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3